Cost-effectiveness of GRAZAX ® for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe

Allergic rhinoconjunctivitis is a global health problem. Around 14 million people in Spain, France, Italy, and Austria suffer from grass pollen induced allergic rhinitis. Standard care only provides symptoms relief, while allergen specific immunotherapy (SIT) treats the underlying cause of the disea...

Full description

Saved in:

Bibliographic Details
Published in:	Respiratory medicine Vol. 101; no. 9; pp. 1885 - 1894
Main Authors:	Canonica, G.W., Poulsen, P.B., Vestenbæk, U.
Format:	Journal Article
Language:	English
Published:	Oxford Elsevier Ltd 01.09.2007 Elsevier Elsevier Limited
Subjects:	Adolescent Adult Aged Allergen specific immunotherapy Allergens - economics Allergens - therapeutic use Biological and medical sciences Conjunctivitis, Allergic - economics Conjunctivitis, Allergic - prevention & control Cost-Benefit Analysis Cost-effectiveness Desensitization, Immunologic - economics Desensitization, Immunologic - methods Drug Costs - statistics & numerical data Female Grass allergen tablet Grass pollen allergy Health Resources - utilization Humans Male Medical sciences Middle Aged Non tumoral diseases Otorhinolaryngology. Stomatology Pneumology Poaceae Pollen - immunology Prospective Studies Pulmonary/Respiratory QALY Quality-Adjusted Life Years Rhinitis, Allergic, Seasonal - economics Rhinitis, Allergic, Seasonal - prevention & control Rhinoconjunctivitis Tablets Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology Europe QALY Grass pollen allergy Rhinoconjunctivitis Allergen specific immunotherapy Cost-effectiveness Grass allergen tablet Allergy Nose disease Rhinitis Conjunctiva disease Conjunctivitis Prevention Immunotherapy ENT disease Tablet Pollen Public health Cost efficiency analysis Pneumology Immunopathology South Eye disease Treatment Health economy Dosage form Allergen
ISSN:	0954-6111, 1532-3064
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Allergic rhinoconjunctivitis is a global health problem. Around 14 million people in Spain, France, Italy, and Austria suffer from grass pollen induced allergic rhinitis. Standard care only provides symptoms relief, while allergen specific immunotherapy (SIT) treats the underlying cause of the disease. Grazax ® from ALK-Abelló is a new, tablet-based, effective route of SIT for home treatment. The objective was to assess the cost-effectiveness of Grazax ® in four Southern European countries. A prospective pharmacoeconomic analyses was carried out alongside a multinational, clinical trial measuring the efficacy of Grazax ®. Pooled data on resource use and health outcomes were collected. A societal perspective was adopted, and the analysis had a nine-year time horizon. The primary outcome measure was quality adjusted life years (QALYs). Grazax ® was superior to standard care for all efficacy endpoints, including QALYs gained, and resulted in significantly less use of rescue medication and fewer hours missed from work. Grazax ® was cost-effective for all countries for an annual price in the range of €1500–€1900. The result was improved by inclusion of future costs of asthma and exclusion of Spanish trial centers which experienced an exceptionally low pollen season. The analysis illustrates that allergen SIT with Grazax ® for grass pollen induced rhinoconjunctivitis is a cost-effective intervention in Southern Europe.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Undefined-1 ObjectType-Feature-3 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3
ISSN:	0954-6111 1532-3064
DOI:	10.1016/j.rmed.2007.05.003